https://feeds.newsfilecorp.com/company/3274 Latest news from NurExone Biologic Inc., as distributed by TMX Newsfile. en CopyRight (c) 2026, Newsfile Corp. All Rights Reserved. office@newsfilecorp.com (Newsfile Corp.) office@newsfilecorp.com (Newsfile Corp.) Mon, 09 Mar 2026 13:19:22 -0400 https://www.newsfilecorp.com/images/newswire/customer-logos/3274.jpg https://feeds.newsfilecorp.com/company/3274 https://www.newsfilecorp.com/release/283437/NurExone-Biologic-Advances-Manufacturing-and-Regulatory-Roadmap-with-Independent-Batch-Consistency-Results-for-Exosome-Production Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - February 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced results from an independent proteomic analysis conducted at the Technion - Israel Institute of Technology. which evaluated multiple production batches of NurExone's exosomes. The results support the...<img src="https://api.newsfilecorp.com/newsinfo/283437/156" id="156" width="2" height="2" style="width: 1px; height: 1px;border: 0px solid;" /> Tue, 10 Feb 2026 16:03:00 -0500 en https://www.newsfilecorp.com/release/283437 https://www.newsfilecorp.com/release/172670/NurExone-Announces-Appointment-of-New-Director-and-Provides-Corporate-Updates Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - July 7, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) ("NurExone" or the "Company") is pleased to announce that, effective July 6, 2023, Dr. Gadi Riesenfeld has been appointed to the board of directors of the Company replacing Mr. Ron Mayron, who resigned for personal reasons.Dr. Riesenfeld has served on the board of directors and as president of several bio-pharmaceutical companies, including Kamapharm Ltd., Galisar Ltd.,...<img src="https://api.newsfilecorp.com/newsinfo/172670/156" id="156" width="2" height="2" style="width: 1px; height: 1px;border: 0px solid;" /> Fri, 07 Jul 2023 09:23:00 -0400 en https://www.newsfilecorp.com/release/172670 https://www.newsfilecorp.com/release/165846/NurExone-Engages-Investor-Relations-Service-Provider Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, announced that it has engaged Litchfield Hills Research, LLC ("Litchfield") to perform investor relations services and activities, as defined in accordance with the policies of the TSX Venture Exchange...<img src="https://api.newsfilecorp.com/newsinfo/165846/156" id="156" width="2" height="2" style="width: 1px; height: 1px;border: 0px solid;" /> Fri, 12 May 2023 08:00:00 -0400 en https://www.newsfilecorp.com/release/165846 https://www.newsfilecorp.com/release/165187/NurExone-Announces-Equity-Incentive-Plan-Grants-and-Director-Resignation Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 8, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, announces that it has granted an aggregate of 1,145,520 incentive stock options ("Options") and 1,275,000 restricted share units ("RSUs") under the Company's equity incentive plan to certain officers and directors of...<img src="https://api.newsfilecorp.com/newsinfo/165187/156" id="156" width="2" height="2" style="width: 1px; height: 1px;border: 0px solid;" /> Mon, 08 May 2023 08:51:00 -0400 en https://www.newsfilecorp.com/release/165187